- Join A Case
Class Action Cases
Join the case to recover your losses. Click "Join this Class Action" above.
Solid Biosciences Inc.
According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) Solid Biosciences’ lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) as a result, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading. When the truth was revealed to the investing public, Solid Biosciences’ share price fell $18.19 per share in the aggregate, causing shareholders harm.
Case has been filed